P.O. Box 303
Uppsala 751 05
46 1 87 80 88 00
Full-time employees: 126
|Mr. Nikolaj Sorensen||Pres & CEO||5.83M||N/A||1972|
|Mr. Fredrik Jarrsten||Exec. VP & CFO||N/A||N/A||1967|
|Ms. Cecilia Coupland||Sr. VP & Head of Operations||N/A||N/A||1976|
|Lena Wange||Investor Relations & Communications Director||N/A||N/A||N/A|
|Mr. Robert Ronn||Sr. VP and Head of R&D||N/A||N/A||1976|
|Dr. Edward Kim M.B.A., M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Mr. Robert A. Deluca||Pres of Orexo US Inc||N/A||N/A||1961|
|Mr. Jesper Lind||Advisor||N/A||N/A||1960|
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Orexo AB (publ)’s ISS governance QualityScore as of 1 March 2023 is 5. The pillar scores are Audit: 8; Board: 1; Shareholder rights: 1; Compensation: 10.